CATALYST PHARMACEUTICALS INC (CPRX)
Health Care · Specialty Pharmaceuticals — Rare Genetic & Neuromuscular Diseases · NASDAQ
Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from established and newly approved products.
What CATALYST PHARMACEUTICALS INC does
Catalyst Pharmaceuticals develops and commercializes pharmaceutical products for rare diseases, primarily focused on neuromuscular conditions. The company markets FIRDAPSE® (amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS) and recently commercialized AGAMREE® (vamorolone), a novel corticosteroid for Duchenne muscular dystrophy (DMD) approved by the FDA in October 2023. The company operates through direct sales and support programs including the Catalyst Pathways® Program to assist patients in accessing therapies.
Themes: Duchenne muscular dystrophy (DMD), Lambert-Eaton myasthenic syndrome, Neuromuscular disorders, Rare disease therapeutics, Pediatric rare diseases, Sarepta Therapeutics (SRPT), Solid Biosciences (SLDB), PTC Therapeutics (PTCT), Atheneum Pharma, Patent litigation exposure: ongoing Paragraph IV patent challenges against FIRDAPSE® (case against Hetero scheduled for trial March 2026) could result in generic competition and erosion of exclusivity and revenue
Fundamentals
- Price$31.49 as of 2026-07-21 close
- Market cap$3.9B as of 2026-07-21
- 1-year return+49.9% 2025-07-21 close $21.01 → 2026-07-21 close $31.49
- P/E17.42 as of 2026-09-02
- Net margin+37.1% as of 2026-09-02
- Gross margin+86.0% as of 2026-09-02
- ROE+23.6% as of 2026-09-02
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)+11.7% as of 2026-09-02
- Revenue CAGR (3y)+40.1% SEC XBRL
- Beta-0.29 as of 2026-09-02
- Last reported earningsn/a no earnings announcement (Form 8-K, Item 2.02) has been filed in our data yet
How CPRX compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-09-02
- net profit margintop 10% 504 covered Health Care peers, as of 2026-09-02
- operating margintop 10% 504 covered Health Care peers, as of 2026-09-02
- gross margintop 25% 384 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 576 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Analyst consensus
- Mean price target$31.67 range $31.50 – $32.00; median $31.50
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CPRX
- Consensus EPS estimate$0.7359 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Uncertainty regarding patent litigation outcomes and potential competition from generic drug entrants (Paragraph IV challengers).","Dependence on a limited portfolio of products, specifically Firdapse and Agamree, for the majority of revenue.","Regulatory, intellectual property, and commercialization risks inherent in the biopharmaceutical industry."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CPRX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
CPRX had 340,264 shares of reported short interest as of the 2026-07-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CPRX had 0.28% of its shares outstanding sold short as of the 2026-07-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1 days to cover at the same settlement.
- Reported short interest (shares) 340,264
- Short interest (% of shares outstanding) 0.28%
- Prior settlement (shares) 7,845,889
- Reported change -95.66%
- Days to cover (reported) 1
Reported to FINRA as of the 2026-07-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amicus Therapeutics (FOLD)
- Sarepta Therapeutics (SRPT)
- PTC Therapeutics (PTCT)
- Rhythm Pharmaceuticals (RYTM)
- Acadia Pharmaceuticals (ACAD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CPRX vs…
CATALYST PHARMACEUTICALS INC is found in…
Frequently asked questions
What does CATALYST PHARMACEUTICALS INC (CPRX) do?
Catalyst Pharmaceuticals develops and commercializes pharmaceutical products for rare diseases, primarily focused on neuromuscular conditions. The company markets FIRDAPSE® (amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS) and recently commercialized AGAMREE® (vamorolone), a novel corticosteroid for Duchenne muscular dystrophy (DMD) approved by the FDA in October 2023.
What sector is CATALYST PHARMACEUTICALS INC (CPRX) in?
CATALYST PHARMACEUTICALS INC (CPRX) is classified in the Health Care sector. Its industry is Specialty Pharmaceuticals — Rare Genetic & Neuromuscular Diseases. It trades on NASDAQ.
Who are CATALYST PHARMACEUTICALS INC's (CPRX) competitors?
Notable peers of CATALYST PHARMACEUTICALS INC (CPRX) include Amicus Therapeutics, Sarepta Therapeutics, PTC Therapeutics, Rhythm Pharmaceuticals and Acadia Pharmaceuticals. This peer set is informational only — not financial advice.
Where does stocks-llm's data on CPRX come from?
Fundamentals and prices come from market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-09-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.